However, the results of the study by Cai et al., 2020 [116] showed that in hypertensive patients receiving ACE inhibitors/angiotensin receptor blockers (ARBs), there was no increase in the frequency of COVID-19 progression to a severe form compared to patients taking other antihypertensive drugs. This evidence concerns the gene ACE and COVID-19.